Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.45 |
| ▸ | ADA | P00813 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838191 | 0.85 | ADORA2A (0.47) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL1738696 | 0.82 | ADORA2A (0.61) | ADORA2AADAHIF1APAX8ADORA3 | |
| SCHEMBL2786188 | 0.82 | ADORA2A (0.61) | ADORA2AADAHIF1APAX8ADORA3 | |
| SCHEMBL2786193 | 0.82 | ADORA2A (0.61) | ADORA2AADAHIF1APAX8ADORA3 | |
| SCHEMBL2786772 | 0.82 | ADORA2A (0.61) | ADORA2AADAHIF1APAX8ADORA3 | |
| SCHEMBL12447395 | 0.82 | ADORA2A (0.61) | ADORA2AADAHIF1APAX8ADORA3 | |
| SCHEMBL6833725 | 0.82 | ADORA2A (0.46) | ADORA2AADAPAX8ADORA3ADORA1 | |
| SCHEMBL6833685 | 0.81 | ADORA2A (0.46) | ADORA2AADAPAX8ADORA3ADORA1 | |
| SCHEMBL13604051 | 0.80 | ADORA2A (0.51) | ADORA2AHIF1APAX8ADORA3ADORA1 | |
| SCHEMBL31093987 | 0.80 | PAX8 (0.55) | HIF1APAX8ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501850-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885ADA 13/4885HIF1A 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.